Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/125180| Title: | Interstitial lung disease secondary to oxaliplatin-raltitrexed based chemotherapy |
| Authors: | Gauci, Luca Scerri, Claudia Mifsud, Maria Gauci, Jonathan |
| Keywords: | Interstitial lung diseases Oxaliplatin Drugs -- Side effect Chemotherapy |
| Issue Date: | 2024 |
| Publisher: | University of Malta. Medical School |
| Citation: | Gauci, L., Scerri, C., Mifsud, M., & Gauci, J. (2024). Interstitial lung disease secondary to oxaliplatin-raltitrexed based chemotherapy. Malta Medical Journal, 36(3), 73-77. |
| Abstract: | FOLFOX is a widely used regimen in the management of gastrointestinal malignancies and is a combination of 5-fluorouracil (5-FU), folinic acid, and oxaliplatin. Raltitrexed is an antifolate thymidylate synthase inhibitor which is used as an alternative when 5-FU is not tolerated. Here we present a case of interstitial lung disease as a rare side-effect of oxaliplatin and raltitrexed. Not much is known about the pathophysiology of the condition and most information available in the literature is taken from published case reports. |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/125180 |
| Appears in Collections: | MMJ, Volume 36, Issue 3 |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| MMJ36(3)CR3.pdf | 3.69 MB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.